Evening Washington
Monday, April 12, 2021
  • Africa
  • Asia
  • Europe
  • latest news
  • USA News
  • World
  • Other
    • TECH
    • Health
    • Fashion
    • Sports
    • Business
No Result
View All Result
  • Africa
  • Asia
  • Europe
  • latest news
  • USA News
  • World
  • Other
    • TECH
    • Health
    • Fashion
    • Sports
    • Business
No Result
View All Result
Evening Washington
No Result
View All Result
Home Health

Gene Therapy, New Drug Battle a Rare But Deadly Disease in Kids

admin by admin
November 2, 2017
in Health
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

WEDNESDAY, Nov. 1, 2017 (HealthDay News) — Babies born with a previously untreatable degenerative nerve disease now have two fresh sources of hope for their future.

Two innovative new therapies for spinal muscular atrophy (SMA) type 1 have proven highly effective in clinical trials, researchers report.

RELATED POSTS

Covid-19: White House criticises ‘chaotic’ vaccine rollout

Type 2 diabetes: Mindfulness shown to lower high blood sugar levels – how to practice it

Babies with SMA are born without the gene that promotes production of survival motor neuron (SMN) protein. Without this protein, nerve cells in the spinal cord and brain stem stop working and start to die off.

These babies slowly lose the ability to move their arms and legs. Those with the most severe form, SMA type 1, eventually lose the ability to breathe on their own and rarely survive beyond 2 years of age.

Two research groups say they've produced breakthrough therapies for these children.

First, a new genetic treatment employed a DNA-loaded virus to replace the missing SMN1 gene with a fresh, healthy copy of the gene.

Second, an already-approved drug called nusinersen (Spinraza) was used to promote production of the crucial nerve protein by a backup gene called SMN2.

Both approaches increased survival in babies with SMA and preserved or improved their motor function, the researchers said.

"These are the first realistic treatment options for SMA," said Dr. Ans van der Ploeg. She is chair of the Center for Lysosomal and Metabolic Diseases at Erasmus MC University in Rotterdam, the Netherlands.

Both therapies aim to increase production of SMN protein in the motor neurons and thereby improve the survival and function of motor neurons, she said. This leads to better muscle and respiratory function and survival, added van der Ploeg, who wrote an editorial accompanying the two clinical trial reports.

About one in every 11,000 babies is born with SMA, and six in 10 of them have type 1, said Dr. Richard Finkel. He is chief of neurology at Nemours Children's Hospital in Orlando, Fla., and lead researcher of the nusinersen clinical trial.

The gene therapy treatment was tested in 15 babies with SMA type 1. All received one intravenous dose of a genetically engineered virus containing the new copy of the SMN gene. The virus is named AVXS-101. This was a phase 1 trial to test safety.

"We are trying to replace SMN1 with enough gene that works in enough nerve cells to change function," said lead researcher Dr. Jerry Mendell, director of neuromuscular disorders and neurosciences at Nationwide Children's Hospital in Columbus, Ohio.

All 15 patients treated with AVXS-101 are still alive, Mendell said, and some are thriving. Higher doses produced better responses.

"All the patients in the trial have improved with the exception of one," Mendell said. "We have patients living out past three years now. And we had patients who actually could walk and run and play."

Nusinersen was tested in 80 babies at 31 hospitals as part of a phase III trial prior to its 2016 approval.

"The drug is kind of novel," Finkel said. "It's not your standard off-the-shelf pharmacy kind of drug. It's similar to a little piece of DNA."

The drug targets the SMN2 gene, a backup gene to the SMN1 gene missing in these babies. It is injected into the spinal fluid. Patients undergo four "loading doses" via lumbar punctures within the first two months, and receive maintenance doses every four months, Finkel said.

Nusinersen amps up protein production by the SMN2 gene, potentially halting progression of nerve damage.

In the trial, 41 percent of infants who received the earliest treatment with nusinersen and 51 percent of infants in the final analysis experienced stable or improved motor function, the researchers reported.

Babies treated with nusinersen also were more likely to survive. The risk of death was 63 percent lower in the nusinersen group compared with the control group, the findings showed.

Results were so promising that the clinical trial was halted early so the control group could receive nusinersen, the study authors said.

"This study shows the drug has a clinically meaningful response with a higher likelihood of improved survival and motor function," Finkel said.

Nusinersen, made by Biogen, is available for treatment now.

AVXS-101 will proceed to broader clinical trials involving more children at multiple hospitals, Mendell said.

Neither treatment had any clinically significant side effects, according to the researchers. The treatments do not constitute a full cure for children who have already developed symptoms of SMA. However, both research teams hope that kids treated before symptoms arise won't suffer any degenerative nerve loss.

Finkel said, "If we can get these babies before they show these signs of weakness, I think that's going to give the best chance for the most robust response, possibly even a cure."

Van der Ploeg added that younger, less severely affected patients had a better chance of a good response in the trials. Also, while the gene therapy pilot trial results are promising, more data are required, she noted.

The nusinersen trial was paid for by Biogen and the drug's developer, Ionis Pharmaceuticals. The AVXS-101 trial received funding from AveXis, developer of the designer virus.

Results of the studies were published in the Nov. 2 issue of the New England Journal of Medicine.

More information

For more on spinal muscular atrophy, visit the Nemours Foundation.

Let's block ads! (Why?)

Original Article

ShareTweetPin
admin

admin

Related Posts

Covid-19: White House criticises ‘chaotic’ vaccine rollout

Covid-19: White House criticises ‘chaotic’ vaccine rollout

by admin
January 24, 2021
0

A senior White House official has criticised the Trump administration's rollout of the Covid-19 vaccine calling it "chaotic" and "very...

Type 2 diabetes: Mindfulness shown to lower high blood sugar levels – how to practice it

Type 2 diabetes: Mindfulness shown to lower high blood sugar levels – how to practice it

by admin
November 24, 2020
0

Type 2 diabetes is characterised by a battle with high blood sugar levels, which can inflict serious damage on the body. High...

Prince George’s Approves Requiring Healthy Kids’ Meals at Restaurants

Prince George’s Approves Requiring Healthy Kids’ Meals at Restaurants

by admin
November 19, 2020
0

A healthy meal and drink will soon be the required default option for kids’ meals at all restaurants in Prince...

Asian Games: Two Indonesian skateboarders secure ticket to final

by webadmin
October 11, 2020
0

When we get out of the glass bottle of our ego and when we escape like the squirrels in the...

Burkina Faso: Growing Violence Threatens Health Care

Burkina Faso: Growing Violence Threatens Health Care

by admin
September 10, 2019
0

Away from the worlds attention, Burkina Faso has been slipping into violence. In less than a year, t..

Next Post

Liposuction May Ease Limb Swelling in Cancer Patients

Sadiq Khan taps Bloomberg to help draft London's smart city strategy

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sport

Winners and losers from men’s NCAA Tournament second-round games

Winners and losers from men’s NCAA Tournament second-round games

March 23, 2021
Mets retaining Luis Rojas as manager

Mets retaining Luis Rojas as manager

November 24, 2020
  • 22M Fans
  • 85 Followers
  • 113k Subscribers
  • 657 Followers
  • 23k Followers

MOST VIEWED

  • ‘Amphan’ may bring first flood of year in Assam: CWC

    ‘Amphan’ may bring first flood of year in Assam: CWC

    0 shares
    Share 0 Tweet 0
  • Playboy Model Marisa Papen Arrested For Dragging Cross In Front Of Vatican While Naked

    0 shares
    Share 0 Tweet 0
  • Russia Scores Gold In Women’s Figure Skating, Leaving USA Ladies Without Medals

    0 shares
    Share 0 Tweet 0
  • 11 Effortless Ways to Wear Adidas Pants Like a Street Style Pro

    0 shares
    Share 0 Tweet 0
  • Where to buy Bitcoin in the UK and how does it work

    0 shares
    Share 0 Tweet 0

CATEGORY

  • Africa
  • Asia
  • Business
  • Europe
  • Fashion
  • Health
  • latest news
  • Sports
  • TECH
  • Uncategorized
  • USA News
  • World

SITE LINKS

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Landing Page
  • All Features
  • Get JNews
  • Contact

© 2020 eveningwashington.com.

No Result
View All Result
  • Africa
  • Asia
  • Europe
  • latest news
  • USA News
  • World
  • Other
    • TECH
    • Health
    • Fashion
    • Sports
    • Business

© 2020 eveningwashington.com.